CIDARA THERAPEUTICS INC. - COMMON STOCK

Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)

31 Jul 2023 15:30:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program

20 Jul 2023 16:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Added to Russell Microcap® Index

26 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

22 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

20 Jun 2023 08:55:48 By Nasdaq GlobeNewswire

Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit

13 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

11 May 2023 15:37:55 By Nasdaq GlobeNewswire

Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

03 May 2023 15:30:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™

24 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Cidara Therapeutics to Participate in Upcoming Investor Conferences

31 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

23 Mar 2023 06:12:23 By Nasdaq GlobeNewswire

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

22 Mar 2023 16:23:28 By Nasdaq GlobeNewswire

Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress

07 Mar 2023 15:15:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock

07 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

03 Mar 2023 08:14:34 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock

02 Mar 2023 15:14:39 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

01 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Cidara to Present at ESMO Targeted Anticancer Therapies Congress

28 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

14 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program

01 Feb 2023 07:00:01 By Nasdaq GlobeNewswire